Table 1.
Values and fold resistance of all the inhibitors used on A375 and B16F10 models.
| Sl. No. | Inhibitor | Human Melanoma Cells (A375) | Mouse Melanoma Cells (B16F10) | ||||
|---|---|---|---|---|---|---|---|
| IC50 | Fold Resistance | IC50 | Fold Resistance | ||||
| Control | Resistant | Control | Resistant | ||||
| 1. | LDN193189 (μM) | 1.5 ± 0.4 | 3.1 ± 0.8 | 2.03 | 2.8 ± 0.3 | 4.6 ± 0.5 | 1.65 |
| 2. | SP600125 (μM) | 5.6 ± 1.3 | 8.0 ± 1.0 | 1.42 | 5.2 ± 0.9 | 8.3 ± 1.5 | 1.59 |
| 3. | IWP-2 (μM) | 12.8 ± 1.9 | 12.1 ± 1.1 | 0.95 | 73.3 ± 2.5 | 99.1 ± 2.7 | 1.35 |
| 4. | VPA (mM) | 2.59 ± 0.1 | 3.56 ± 0.4 | 1.37 | 1.44 ± 0.1 | 1.91 ± 0.1 | 1.32 |
IC50: concentration of drug which shows 50% growth inhibition. The fold resistance was calculated from IC50 values using the following formula: Fold resistance = IC50 drug-resistant cells/IC50 parental cells. The IC50 values were calculated from the dose-response curves in Figure S1 (for LDN193189, SP600125, IWP2, and valproic acid (VPA)).